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Abstract
Cancer is the second leading cause of mortality in the United States. There are 
several therapeutic regimens employed to mitigate the mortality rate of cancer. 
This includes the use of chemotherapy, radiation, immunotherapy, and precision 
medicine/targeted therapy. Targeted therapy involves the use of drugs that target 
a specific pathway or biomolecule compromised in cancer for cancer treatment. 
Aberrant expression of epigenetic enzymes has been well documented for their 
contribution in driving tumorigenesis and other cancer hallmarks. Hence, there 
is an urgent need for novel drug discovery and development in epigenetics to help 
combat various cancer morbidities. Herein, we review the roles and consequences 
of dysregulated function of several epigenetic enzymes, with a focus on histone 
methyltransferases (HMTs). Additionally, we discussed the current efforts made 
in the development of small molecule inhibitors for a few representative HMTs 
implicated in different cancers. Furthermore, the common screening assays used 
in discovering potent small molecule inhibitors were also detailed in this chapter. 
Overall, this book chapter highlights the significance of targeting HMTs in different 
cancers and the clinical application potentials/limitations faced by the developed or 
emerging small molecule inhibitors of HMTs for the purpose of cancer therapy.
Keywords: cancer, drug discovery, epigenetics, histone methyltransferases,  
small molecule inhibitors
1. Introduction
Since the conception of the term “epigenetic landscape” by Conrad Waddington in 
1940, the field of epigenetics has rapidly evolved with technological advances. In the 
study of embryonic development, it was observed that a single gene has the ability to 
produce different phenotypes, so epigenetics was used to describe the mechanisms 
through which that happens [1]. Today, epigenetics is defined as the study of changes 
in organisms caused by modification of gene expression through addition and 
removal of chemical groups to nucleotides and proteins rather than the alteration 
of the genetic code itself [2]. The human genome contains approximately 3 billion 
bases of nucleotides and they are compacted into chromosomes in the nucleus via 
histone proteins. About 146 base pairs of nucleotides are wound around core  
histone octamers and are sealed with the linker histone (H1) to form a nucleosome.  
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The linker histone connects multiple nucleosomes in the chromatin. The core 
histone octamers consist of two dimers of H2A-H2B and a tetramer of H3-H4 
proteins [3]. These core histones contain two regions namely: the histone fold 
and the histone tails. The C-termini of H2A and N-termini of other core histones 
protrude out of the fold to form histone tails and are commonly subjected to 
epigenetic modifications [4]. DNA and RNA also undergo epigenetic modifications, 
and these modifications control gene expression and maintain genomic integrity. 
Epigenetic enzymes can be broadly categorized into three components: the writers, 
the erasers, and the readers. Writers are enzymes responsible for adding the modi-
fications, erasers remove it, and readers recognize it. These modifications include 
but are not limited to methylation, acetylation, phosphorylation, ubiquitination, 
GlcNAcylation, and SUMOylation [5].
DNA mainly undergoes methylation, and this occurs through the action of a 
family of DNA methyltransferases (DNMT1, DNMT2, DNMT3a, and DNMT3b). 
DNMTs covalently modify DNA by catalyzing the transfer of methyl group from 
S-adenosylmethionine (SAM) to the C5 position on a cytosine ring. DNA methyla-
tion mostly occurs in CpG islands, a region of the DNA rich in cytosine and guanine 
base repeats [6]. This modification to the DNA functions to repress transcription 
when it occurs in gene promoters and regulates splicing when it occurs in gene 
bodies [7]. DNA methylation is a reversible mechanism, which can be either pas-
sive through reduced DNMT1 activity during DNA replication or active through 
activity of its erasers, DNA demethylases. For instance, the ten-eleven transloca-
tion proteins (TET 1/2/3) are human demethylases that catalyze the oxidation of 
5-methyl-cytosine to 5-hydroxymethylcytosine [8]. Following DNA methylation, 
often readers such as the family of methyl binding domain proteins recognize the 
methylation marks to drive transcriptional repression [9].
RNA is also methylated on C5 position of cytosine (m5C) and N6 position 
of adenosine ring(m6A) by family of RNA methyltransferases such as Dnmt2, 
NOP2/Sun, Mettl3, and Mettl14. RNA methylation can be reversed by these RNA 
demethylases: fat mass and obesity associated protein (Fto) and α-ketoglutarate-
dependent dioxygenase alkB homolog 5 (AlkBH5) [10]. Methylation modification 
on RNA is interpreted by readers such as the YTH domain family, and they mediate 
RNA splicing, export, stability, maturation, decay, secondary structure switch, 
and translation [11]. There have also been reports of RNA acetylation by NAT10 
acetyltransferase, which functions to promote mRNA stability and efficiency in 
translation [12].
Moving up the central dogma, lysine and arginine residues on histone proteins 
are mostly subjected to various post-translational modifications by their respective 
epigenetic enzymes to either activate or repress transcription. Although the focus 
of this chapter is histone methylation, histone acetylation will be briefly discussed. 
Histone methyltransferases (HMTs) and histone acetylases (HATs) are the writers 
of histone methylation and acetylation, respectively. HMTs can be further subdi-
vided into lysine methyltransferase (KMT) and protein arginine methyltransferase 
(PRMT) [13]. The families and functions of HMTs will be further explored in this 
chapter. On the other hand, several HATs have been discovered, with the major 
ones being the GNATs (Gcn5-N-acyltransferases), the MYST families, and p300/
CBP [5]. These enzymes catalyze the transfer of acetyl group from acetyl Co A 
to the side chain amino group on histone lysine residues, inducing transcription-
ally active chromatin [13]. Histone deacetylases and histone demethylases are 
involved in reversing the histone modifications discussed above. The families of 
lysine-specific histone demethylase 1 (LSD1) and Jumonji histone demethylases 
(JMJD) mediate the removal of methyl groups from histone through respective 
mechanisms [13, 14]. Readers of histone methylation include protein containing 
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the MBT, PHD, chromo, Tudor, double/tandem Tudor, Ankyrin Repeats, zf-CW, 
WD40, and PWWP domains [15].
Given this array of epigenetic enzymes and their broad spectrum of function in 
regulating several gene expression in humans, the roles of epigenetic enzymes have 
been implicated in tumorigenesis. The epigenome of cancerous cells has widespread 
changes in DNA methylation and histone modification patterns [16]. For instance, 
hypermethylation of CpG islands in the promoter of chromodomain helicase DNA-
binding protein 5 (CHD5), a chromatin remodeler, was observed in colon, breast, 
hepatocarcinoma, cervix, and glioma cell lines [17]. This results in the downregulation 
of CHD5, which plays a tumor suppressive role in cells. Similarly, hypomethylation of 
DNA at promoters of oncogenes such as insulin-like growth factor 2 (IGF2) has been 
observed in breast and colon cancers. The differential methylation patterns on pro-
moters of tumor suppressors and oncogenes mediated by increased/reduced activity of 
DNMTs and TETs enzymes have been used as biomarkers to predict the predisposition 
of individuals to cancer [18]. Also, aberrant expression of histone acetyl transferases 
(HATs) and histone deacetylases (HDACs) has been linked to tumor development. 
Studies have shown that that p300/CBP acts as a coactivator with c-Myb to activate the 
transformation of fusion oncoproteins in myeloid leukemia [19]. Increased expression 
of HDACs was reported in gastric, prostate, colon, and breast carcinomas, and this 
results in repression of tumor suppressor genes like cyclin-dependent kinase inhibitor, 
see p21 [20]. Of all the histone modifications, histone methylation dysregulation is 
mostly attributed to poor prognosis in several cancers, which we will further elaborate 
in detail in Section II “Histone Methyltransferases in Cancer.”
As these epigenetic enzymes’ activity has been altered in cancer and contributes 
to the genomic instability in cancer cells, it is crucial to develop targeted therapeutic 
treatments to restore their normal function. Aside from surgery, some common 
treatment options for cancer patients can be broadly categorized as thus: chemo-
therapy, immunotherapy, radiotherapy, and precision medicine/targeted therapy 
[21]. These classes of treatments are not mutually exclusive and can be used in 
concert for treating cancer patients. Among these different therapeutic approaches, 
targeted therapy is the future for cancer treatment. Targeted therapy involves the 
use of drugs that target a specific biological molecule/pathway or drug treatment 
that requires genome profiling of an individual before it can be administered [22]. 
For optimal development of drugs for targeted therapies, it is important to identify 
a well-defined biological target whose activity contributes to one to several hall-
marks of cancer including propagating growth signals, evading immunosurveil-
lance, cell death resistance, activating metastatic programs, suppressing antigrowth 
signals, inducing angiogenesis, and enabling immortal replication of cells [23, 24]. 
For example, cancer patients whose tumors are driven by high activity of epidermal 
growth factor receptor (EGFR) signaling can be treated with specific monoclonal 
antibodies or small molecule kinase inhibitors antagonizing the aberrant signaling, 
and thereby reducing tumor proliferation [25]. Similarly, targeting an epigenetic 
enzyme, PRMT5, which is highly expressed in gastrointestinal cancers, with small 
molecule inhibitor, PR5-LL-CM01, was shown to slow down cancer cell growth 
and invasion in vitro [26]. The limitations of targeted therapies include cancer cell 
resistance to drug treatment by activating a parallel pathway or sometimes targets 
can undergo mutation, making drug accessibility to target difficult [27].
Given the myriad of biological targets that have been discovered to mediate 
cancer progression, there has been increasing interest in the development of small 
molecule inhibitors capable of decreasing the activity of those targets. Small mol-
ecules are intracellular targeting compounds with low molecular weight of less than 
900Da. They can modulate their target activity as an agonist or antagonist [23]. 
The growing interest in the use of small molecules for drug development is not only 
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due to their small size, which enables easy permeability into the cell, but also their 
desirable pharmacokinetics, pharmacodynamics, longer shelf life, and easy synthe-
sis [28]. Several small molecule modulators have been developed into drugs to treat 
various types of cancers. The range of small molecule inhibitors developed to enable 
tumor regression can be broadly categorized into small molecule kinase inhibitors, 
proteasome inhibitors, metalloproteinases and heat shock protein inhibitors, and 
apoptosis targeting inhibitors [29]. The most common small molecule inhibitors, 
kinase inhibitors, have been used to inhibit the several protein kinases whose activ-
ity is dysregulated in cancers. The first tyrosine kinase inhibitor drug, Imatinib, 
is a small molecule ATP analog that competitively inhibits Bcr-Abl fusion protein 
kinase activity in chronic myeloid leukemia patients [30]. Similarly, a number of 
small molecule inhibitors targeting epigenetic enzymes implicated in tumorigenesis 
are in development or have been FDA approved for cancer treatment. For instance, 
drugs like belinostat and romidepsin are HDAC inhibitors that are FDA approved 
for the treatment of lymphoma [31]. After the first clinical trial in 2014, tazemeto-
stat, an EZH2 small molecule inhibitor, moved to phase 2 clinical trial and was fast 
tracked by FDA in 2017 for the treatment of follicular lymphoma [32]. The use of 
tazemetostat for treatment of epithelioid sarcoma in adults 16 years and above was 
also granted accelerated approval by the FDA. These examples, among many others, 
show the potentials of epigenetic modifiers as a druggable target for cancer treat-
ment. More of these small molecule inhibitors for histone methyltransferases will 
be explored later on in this chapter. However, challenges in the clinical application 
of certain small molecule inhibitors as drugs remain due to their off-target effects or 
development of resistance by cancer cells [29].
2. Histone methyltransferases in cancer
As we mentioned above, epigenetic enzymes, including histone methyltransfer-
ases, are novel targets for cancer therapy. In this section, we will review the role of 
histone methyltransferases in cancer.
2.1 Lysine methyltransferases
Lysine methylation of histones was first characterized in the 1960s [33, 34] 
and was initially described as an “irreversible” post-translation modification. 
This dogma was challenged by the discovery of histone demethylases by Shi et al. 
indicating a dynamic function of methylation allowing the addition and removal of 
methyl groups [35]. The proteins responsible for the addition of methyl groups to 
histones are known as lysine methyltransferases (KMTs). KMTs are broadly defined 
as SET [Su(var)3-9, Enhancer of Zeste, Trithorax] domain-containing proteins and 
non-SET domain-containing proteins [36]. The only non-SET domain-containing 
KMTs identified so far are DOT1 (disrupter of telomeric silencing 1) family mem-
bers, which methylate K79 of histone H3 and which also do not share structural 
similarities with SET-containing proteins [37–39]. KMTs act by catalyzing the 
transfer of 1~3 methyl groups to lysine residues of histone and non-histone proteins 
through the addition of the cofactor S-adenosyl methionine (SAM), which acts as 
a methyl donor group [40]. In the case of SET domain-containing proteins, SAM 
interacts and orients with a lysine residue of the substrate histone tail within the 
catalytic pocket of the SET domain. Then, a tyrosine residue acts to deprotonate the 
ε-amino group of the lysine residue, which allows the lysine chain to nucleophili-
cally attack the methyl group of the SAM molecule, transferring the methyl group 
to the lysine side chain [41]. In the case of non-SET domain-containing KMTs, 
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the enzyme DOT1 acts to methylate a lysine residue in the histone core [40]. As 
we described above, histone methylation is a critical epigenetic modification of 
chromatin that can impact genomic stability, alter expression of different genes, 
determine cell lineage, alter DNA methylation, as well as control cell mitosis [42].
SET-containing proteins have been characterized in greater detail than non-
SET-containing proteins. SET domain proteins are characterized as seven families 
of the superfamily of KMTs: SUV39, SET1, SET2, EZ, RIZ, SMYD, and SUV4-20 
[36]. There are also several SET domain proteins that do not fall into these groups 
including SET7/9 and SET8 [36]. The SUV39 family has been characterized the 
most out of these groups of KMTs. Specifically, Schizosaccharomyces pombe Cryptic 
loci regulator 4 (CLR4), human SUV39H1, and murine SUV39H2 were among 
the first identified SET domain protein lysine methyltransferases characterized 
when their sequence homology between their SET domains was discovered. These 
proteins methylate lysine 9 of histone H3 (H3K9) [43]. SET1 and SET2 complexes 
are involved in the RNA polymerase II holoenzyme [44, 45]. TSET1 acts to tri-
methylate H3K4 and is associated with early gene transcription as opposed to 
SET2-mediated methylation of H3K36, which is associated with later transcrip-
tional elongation of downstream genes. The mammalian nuclear-receptor-binding 
SET domain-containing protein (NSD1, a member of the SET2 family) has an 
important function in methylation of H3K36 and H4K20 in development [46]. Lu 
et al. in our research group also reported that NSD1 could methylate non-histone 
protein, NF-κB, at K218/221 of its p65 subunit, leading to the activation of NF-κB 
and its downstream target gene expression [47–50]. Another example is SETDB1, 
a H3K9 methyltransferase, which is amplified in primary tumors of lung cancer 
patients and contributes to the invasive phenotype of tumor cells [51]. Additionally, 
SETDB1 methylates H3K9 in euchromatin, and is also required for development 
[52]. Human SET7/9 acts to mono-methylate H3K4 [53]. Furthermore, SET domain 
enzymes’ functions are not specifically tied to histone methylation. Human SET7/9 
methylates K189 on transcription factor TAF10, which increases RNA polymerase 
II affinity and transcriptional activity, thereby expression of TAF10-dependent 
genes [54]. SET7/9 is also involved in p53 methylation, which increases its stability 
[55]. These examples described are only a few of the many SET-containing proteins 
of which over 50 different proteins have been discovered [56]. While SET domain 
proteins are typically referred to as histone lysine methyltransferases, it may be 
more accurate to refer to them as protein lysine methyltransferases due to their 
identification of non-histone targets for these KMTs.
These examples of SET and non-SET domain-containing proteins exhibit 
the importance of KMTs in the regulation of histone and non-histone proteins. 
Therefore, it is not surprising that dysregulation of KMT function can result in 
dysregulation of cellular functions. Specifically several KMTs have been associated 
with tumorigenesis of several different cancers.
H3K9 methyltransferases SETDB1 and G9a are both known to have roles in gene 
silencing and embryo development [57]. G9a regulates cancer metabolism in several 
types of cancer [58]. Overexpression of G9a is associated with worse prognosis 
in patients with prostate cancer. Intriguingly, G9a knockdown in breast and lung 
cancer has been shown to promote E-cadherin expression and thus tumor metasta-
sis [59, 60]. Moreover, G9a’s higher expression predicts higher mortality of ovarian 
cancer patients [61] and is reported to be associated with cell growth and prolifera-
tion in neuroblastoma [57]. Furthermore, G9a has been shown to have a critical 
role in the development of pancreatic carcinoma and acute myeloid squamous cell 
carcinoma. G9a-dependent repression of genes is also associated with development 
of leukemia as well as squamous cell carcinomas [57]. SETDB1 is another H3K9 
methyltransferase reported to play a role in numerous types of human cancer. 
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SETDB1 is involved in regulation of several cellular processes, including apoptosis, 
DNA damage repair, and regulation of transcription factors [62]. SETB1 is associ-
ated with oncogenic activity and is upregulated in several cancers including lung 
cancers, gliomas, and prostate cancer [63–66]. For instance, in lung cancer, over-
expression of SETDB1 promotes invasiveness and knockdown reduced lung cancer 
cell growth. In gliomas, cell proliferation was reduced by suppression of SETDB1. 
In prostate cancer, downregulation of SETDB1 led to reduced cellular proliferation, 
migratory ability, and invasive ability.
EZH2 (Enhancer of zeste homolog 2), a H3K27 methyltransferase, plays an 
important role in transcriptional repression [36]. EZH2 plays a critical regula-
tory role in as many as 46 types of human cancer [57, 67]. Typically, EZH2 is 
overexpressed in cancers, and its high expression has been linked to worse patient 
survival. For instance, EZH2 downregulation in breast cancer can block cell growth 
and survival [68]. Moreover, EZH2 knockdown inhibits invasive ability and cellular 
proliferation in prostate cancer [69]. Additionally, EZH2 has also been shown to 
have roles in gliomas and renal cell carcinoma, wherein decreased EZH2 expression 
reduces cellular proliferative ability and promotes apoptosis [70].
Another example is SMYD3 (SET and MYND domain-containing 3). It is a KMT 
that methylates H3K4 and is extremely important for initiation of transcription. 
High SMYD3 activity is indicative of an epigenetic signature of active enhancers 
[71]. SMYD3 knockdown in colorectal cancer can impair cellular proliferation [72]. 
In breast cancer, knockdown of SMYD3 also inhibits cell growth, and overexpres-
sion can promote carcinogenesis by regulation of the Wnt signaling pathways [73]. 
Additionally, reduction of SMYD3 expression in prostate cancer inhibits cellular 
proliferation, migration, and colony formation [74].
H3K36 methylation is critical for transcriptional elongation, and H3K36 methyl-
transferases have been identified to play important regulatory roles in several types 
of cancer. NSD1, a H3K36 KMT, is involved in prostate cancer androgen receptor 
transactivation, which results in prostate tumorigenesis [75]. Overexpression of 
NSD1 in neuroblastoma reduces cellular growth ability and colony formation [76]. 
NSD1 has also been reported to play a role in myelomas and lung cancers [57]. As we 
described above, our lab also found that NSD1 activates NF-κB to induce its target 
gene expression. The function of these genes is frequently involved in oncogenic 
phenotype, or cytokine, chemokine secretion [47]. Another example is H4K20 
methylation, which is reported to be important for gene transcription. For example, 
overexpression of methyltransferases of H4K20 SUV420H1 and SUV420H2 is asso-
ciated with decreased cell invasiveness in breast cancer, and knockdown increases 
epithelial to mesenchymal transition [77].
DOT1, the only known H3K79 methyltransferase and non-SET containing KMT, 
also plays an important role in cancer development. DOT1 is involved in cell sur-
vival and colony formation in several forms of leukemia [78]. The activity of human 
DOT1L (hDOT1 like) methyltransferase is compromised in mixed lineage leukemia 
(MLL) and is required for maintaining proliferative state of transformed cells [79]. 
Also, downregulation of DOT1 in lung cancer can cause cell cycle arrest and reduce 
cellular proliferation [80].
Together, these examples show several of the pathways regulated by KMTs and 
also highlight the critical importance of tight regulation of these pathways wherein 
dysregulation of KMTs can result in promotion of tumorigenesis.
2.2 Protein arginine methyltransferases
In contrast to KTMs, there is another important family of protein methyltrans-
ferases, namely, protein arginine methyltransferases (PRMTs). It is a family of nine 
7Discovery of Small Molecule Inhibitors for Histone Methyltransferases in Cancer
DOI: http://dx.doi.org/10.5772/intechopen.92830
members (PRMT1-9) and specifically catalyzes the methyl transfer from SAM to 
the guanidine nitrogen (ω-NG) of the arginine residues of protein substrates [81]. 
After the donation of methyl groups, SAM forms S-adenosyl-L-homocysteine 
(AdoHcy, SAH) and methylarginine is produced [81]. There are three forms of 
methylarginine recognized in mammalian cells: ω-NG-monomethylarginine 
(MMA), ω-NG, NG-asymmetric dimethylarginine (ADMA), and ω-NG, N’G-
symmetric dimethylarginine (SDMA) [82]. The family of PRMTs is categorized into 
three major types: type I, II, and III. Type I and II PRMTs first catalyze the forma-
tion of MMA, and then type I PRMTs (PRMT1, 2, 3, 4, 6, and 8) further catalyze 
the formation of ADMA, while type II (PRMT5 and 9) would instead catalyze the 
production of SDMA. For type III PRMTs (PRMT7), they only catalyze the forma-
tion of MMA [83]. These three types of PRMTs methylated similar substrates, such 
as histone, but they also can catalyze different non-histone substrate proteins. 
Additionally, although the majority of PRMTs methylate glycine-arginine-rich 
(GAR) motifs in their substrates [84, 85], some of them display a preference of 
methylation on the proline-glycine-methionine rich (PGM) motifs in substrate 
proteins such as PRMT4 [86, 87], while PRMT5 is characterized with the methyla-
tion of both types of motifs in proteins [86, 88].
PRMTs are widely expressed in mammalian cells and regulate primary cellular 
processes, including cell proliferation and differentiation. The abnormal expression 
of some types of PRMTs such as PRMT1, 4, 5 and 6 frequently leads to tumorigen-
esis and malignancy.
PRMT1 was the first protein arginine transferase recognized in mammals and 
assumes the large fraction of arginine transferases activity in mammalian cells 
[89, 90]. It has been reported that PRMT1 is related to various kinds of cancer. 
Le Romancer et al. suggested that PRMT1 governed the interaction of estrogen 
receptor α (ERα) with steroid receptor coactivator proteins (Src), the p85 subunit 
of phosphatidylinositide 3-kinases (PI3K) and focal adhesion kinase (FAK) [91]. 
PRMT1-mediated ERα methylation is integral for the activation of the Src-PI3K-
FAK signaling pathway [91]. In their subsequent report, the authors further 
demonstrated arginine methylation of ERα by PRMT1 might remarkably activate 
protein kinase B (PKB, also known as AKT) [92]. Another example is methylation 
of Axin by PRMT1. Cha et al. showed that arginine methylation of Axin by PRMT1 
may activate the WNT pathway by destabilizing Axin and promote tumorigenesis 
[93, 94]. Importantly, it is reported that methylation of meiotic recombination 11 
(MRE11, also known as MRE11A) and p53 binding protein 1 (53BP1) by PRMT1 can 
block the DNA repair pathway, contributing to cancer progression [95, 96]. MRE11 
combines with DNA repair protein RAD50 and Nijmegen breakage syndrome 1 
(NBS1) to form MRE11-RAD50-NBS1 complex (MRN complex). The mamma-
lian MRN complex plays significant role in repairing DNA double-strand breaks 
(DSBs). Yu et al. reported that the deficiency of arginine methylation of MRE11 in 
its GAR motif resulted in exonuclease and DNA-binding defects and finally failing 
to repair DNA damage [96]. Interestingly, Boisvert et al. found that 53BP1 could not 
relocalize to DNA damage sites and γ-H2AX formation was decreased in fibroblasts 
treated with methylase inhibitors [95, 97]. Moreover, Mitchell et al. discovered 
that depletion of PRMT1 affected the length and stability of telomere [98]. Since 
dysfunction of both DNA repair pathway and telomere maintenance is known to 
be the cause of cancer, deregulation of PRMT1 may lead to tumorigenesis by these 
pathways.
In addition to PRMT1, another PRMT member, PRMT4 (also known as 
CARM1), is reported to be tightly associated with estrogen-mediated oncogenesis 
of breast cancer through the upregulation of transcription factor E2F1 expres-
sion [99]. Moreover, CARM1 is suggested to be overexpressed in human colon 
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cancer and exert a crucial role in Wnt signaling through mediating the action of 
β-catenin on Wnt target genes as a transcriptional coactivator [100]. Moreover, 
c-fos is a proto-oncogene and overexpressed in a set of cancers. Some groups 
reveal that PRMT4 regulates transcriptional activation of c-fos, and that matrix 
metalloproteinases (MMPs), c-fos target genes, are significantly downregulated in 
CARM1-deficient cells [101]. Therefore, arginine methylation by PRMT4 is related 
to multiple oncogenic signaling pathways.
An important PRMT member that plays a critical role in cancer is PRMT5. As a 
primary type II PRMT, PRMT5 functions in the presence of other binding partners, 
such as MEP50. Hou et al. discovered that E-cadherin expression was remarkably 
repressed by SNAIL and PRMT5 recruited by bridge molecule AJUBA, which was 
favorable for tumor metastasis [102]. It was also reported that p53 can be methyl-
ated on multiple arginine sites by PRMT5 in response to DNA damage [103]. 
Scoumanne et al. proposed that PRMT5 inhibition may promote cancer cells to 
progress toward apoptosis under chemotherapy/radiotherapy [104]. Moreover, Cho 
et al. found methylation of E2F1 by PRMT5 weakened its ability to promote apopto-
sis and repress proliferation, indicating PRMT5 overexpression may enhance cancer 
cells’ growth and survival [105]. It is well known that continuous NF-κB activation 
exists in most cancers. Our group uncovered that PRMT5 dimethylated the p65 
subunit of NF-κB at arginine 30 (R30) to activate NF-κB pathway [106], an impor-
tant transcription factor that is involved in the progression of many cancers. Also, 
PRMT5 is reported to promote its own overexpression in several cancers through a 
feedback loop involving NF-κB signaling [107].
Besides the PRMTs we discussed above, PRMT6 is widely taken as a transcrip-
tional repressor. Neault et al. reported that embryonic fibroblast cells from the 
PRMT6 knockout mouse were subjected to a premature senescence, while the cel-
lular senescence can be rescued in PRMT6 and p53 double knockout mouse embry-
onic fibroblast (MEF) cells [108], affirming growth suppression effect of excess p53 
due to PRMT6 deficiency. Thus, PRMT6 actively suppresses p53 cascade to promote 
tumorigenesis in cancer.
Taken together, many members in the PRMT family have shown essential role 
in cancer development and progression. Thus, it is unsurprising that these PRMTs 
have become the rising targets in cancer therapeutics in recent years.
3.  Discovery of small molecule inhibitors for histone methyltransferases 
in cancer treatment
3.1 Screening assays for epigenetic drug discovery
The timeline of drug development from conception of the idea to a feasible drug 
available in the market for treatment of diseases takes between 12 and 15 years and 
can cost up to $1billion [109]. Drug discovery process begins with identifying a 
druggable biological target that contributes to a disease progression. These targets 
can be identified through text mining from online databases, microarray data 
mining using bioinformatic tools, proteomic data mining from proteomic data-
bases, and chemogenomic data mining, which involves simultaneous exploration 
of multiple cell phenotypes by screening small molecules from chemical libraries 
to a number of biological targets [110]. Then, promising or known targets can be 
validated in vitro and in vivo to confirm that their activity influences phenotype 
associated with a disease. This step is followed by screening or high throughput 
screening (HTS), which describes the process of sifting through compound librar-
ies for molecules with high affinity for a target of interest [111]. The two approaches 
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of developing assays for compound library screening are the biochemical target-
based approach and the cell-based approach. Biochemical target-based approach 
is often employed as the primary screening assay in epigenetic compound screen 
because it allows the direct monitoring of ability of a target activity as opposed to 
cell-based assays wherein changes in cell phenotypes are measured [112]. Listed 
below are some of screening assays used in the preclinical development of drugs for 
epigenetic enzymes.
3.2  AlphaLISA screen (amplified luminescent proximity homogeneous  
assay-linked assay)
AlphaLISA is a high throughput screening approach used to analyze and mea-
sure post-translational modifications, protein-protein interactions, and concentra-
tions of analytes. The robust, highly sensitive, reproducible, miniaturized, scalable, 
and automated nature of AlphaLISA assays earned them their widespread applica-
tion in research and drug discovery. The principle behind AlphaLISA technology is 
based on the mechanism of another methodology, Luminescent oxygen channeling 
immunoassay (LOCI). LOCI involves chemiluminescent reaction of a singlet oxy-
gen transfer and was developed in 1994 by Ullman et al. to quantify latex particle 
binding [113]. Similarly, AlphaLISA assays employ biotinylated antibody bound to 
streptavidin donor beads and an acceptor bead bound to a second antibody. These 
antibodies are specific to different epitope on a protein (could also be product of 
a bimolecular interaction or a modified protein). The binding of these antibodies 
to the proteins brings the donor and the acceptor bead into proximity of at most 
200nm. Upon excitation of donor beads at 680nm, a singlet oxygen is excited from 
the donor bead and this triggers singlet oxygen reaction with the chemical dyes 
(thioxene and europium) on the acceptor bead, which results in chemiluminescent 
emission at 615nm [114, 115]. Multiplate readers equipped with AlphaLISA screen 
detections can be used to record signals. A systematic method used to validate the 
quality of HTS assay output like AlphaLISA is called the Z-factor. The Z-factor is 
calculated by accounting for the positive and negative controls’ mean signal-to-
mean background ratio. Hence, in the design of AlphaLISA assay, to ensure quality 
control, wells containing maximum signal and no signal solution mix must be 
included [116]. This assay is widely optimized to screen for small molecule modula-
tors for different epigenetic enzymes. For example, in our lab, Prabhu et al. used 
an optimized AlphaLISA screen protocol to identify a lead compound capable of 
targeting PRMT5, and subsequently, the compound was shown to be more potent 
in reducing pancreatic and colon cancer cells’ proliferation compared to another 
commercially available compound EPZ015666 [26]. Not only is this assay used to 
screen for compounds for epigenetic targeted therapy, but also they uncover new 
roles of different epigenetic enzymes in cancer. Consequently, together with other 
assays, it was uncovered using AlphaLISA HTS assay that an inhibitor of G9a lysine 
methyltransferase, A-366, limits cell growth and differentiation in leukemic cells 
[117]. Potent small molecule inhibitors for EZH2, a methyltransferase known to 
silence tumor suppressor genes, are also being identified using this particular HTS 
assay [118]. AlphaLISA kits specific for histone methyltransferase modifications, 
among many other epigenetic enzymes, are commercially available for research and 
drug development purposes [119].
3.3 FRET (Förster/fluorescent resonance energy transfer) assay
Discovered in 1946 by Theodor Förster, FRET is cell-based assay that enables 
real-time observance of molecular interactions within cells [120]. This phenomenon 
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depends on the proximal interaction (1-10nm) of a donor fluorophore and an 
acceptor fluorophore, whereby upon excitation, the donor fluorophore transfers 
energy to the acceptor, increasing its emission wavelength [121] (Figure 1). The 
measure of FRET is taken as the ratio of the intensities of the donor/acceptor 
fluorophore. Although highly sensitive in distance, FRET assay does not permit the 
level of sensitivity and high throughput as AlphaLISA [122]. A type of FRET, FLIM-
FRET (fluorescence lifetime imaging FRET) was used to conduct epigenetic bio-
marker screening in ER-positive breast cancer cell line and patients. The utilization 
of FRET in this study was based on the presence of certain histone modifications 
around ERα in the nucleus. Consequently, the assay revealed H3K27ac and H4K12ac 
interaction with ERα, making HATs a potential therapeutic target in compound 
screening [123]. Another study optimized TR-FRET (time-resolved FRET) for high 
throughput screening, following the treatment with HDAC inhibitors, to detect the 
methylation levels of histone 3(H3) in U-2 OS cells using terbium-tagged antibodies 
specific to a particular H3 modification and green fluorescent protein (GFP)-tagged 
H3 [124].
3.4 In silico screen
In silico screening or virtual screening is a common method used in drug dis-
covery as a pre-filtering method for identifying promising compounds that can be 
used for experimental studies. Drug development using this method of screening 
is estimated to save approximately $130 million and 0.8 years per drug [125]. The 
approach to virtual screening can be broadly divided into structure-based methods 
Figure 1. 
Schematic demonstrating the use of FRET for epigenetic screen. In the presence of histone methyltransferase 
and its methyl donor, SAM, a GFP-tagged Histone 3 becomes methylated on lysine-9 (K9) and undergoes FRET 
as terbium (Tb) conjugated antibody binds to the monomethylated K9 (K9me). This leads to increased GFP 
emission at 540nm wavelength (Right arm of the diagram), demonstrating the occurrence of K9 methylation. 
In contrast, when in the absence of K9 methylation mediated by HMTs, due to the addition of potent HMT 
inhibitors (Lower arm of the diagram), FRET does not occur as K9 cannot be methylated and thereby the 
antibody cannot bind to its epitope. As a result, the wavelength of GFP will be at lower end of the emission 
spectra, 520 nm.
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and ligand-based methods. Structure-based approach encompasses docking can-
didate molecules against available 3D structure of the target protein. When there 
is no crystal structure of the target protein, ligand-based approach is more useful 
because it relies on the screening of bioactive ligands of a similar chemical structure 
[126]. This approach is similar to pharmacophore-directed homology modeling: 
a process that involves superposing known active ligands for structurally similar 
targets and then extracting matching chemical properties of the ligand that are 
required for their bioactivity. Pharmacophore from different bioactive molecules 
can be generated using commercially available software such as HipHop, PHASE, 
DISCO, HypoGen, among others [127].
In computer-aided design of epigenetic drugs, there are a plethora of databases 
like ZINC containing over 35 million compounds available for screening. Other 
databases like SPECS, Chembridge, and Enamine have been used to identify inhibi-
tors for most subsets of histone methyltransferases [128]. Molecular dynamics 
simulation also aids in drug discovery as they are employed to understand the 
conformational changes in the different domains of a target protein [129]. For 
instance, a study developed analogs of eosin, a template molecule known for having 
anti-methyltransferase activity, using pharmacophore methods. These molecules 
were docked on to PRMT1, SET7, and CARM1, and the AutoDock analysis revealed 
that compounds that target SAM substrate-binding site were more active in PRMT1 
and CARM1 while those that target lysine and co-factor binding site were more 
promising in SET7 [126].
4. Current small molecule inhibitors of histone methyltransferases
Development of small molecule inhibitors for histone methyltransferases has 
garnered remarkable attention over the past years due to their combined efficacy 
and potency in various cancer treatments. In this section, we will discuss small 
molecule inhibitors of a few HMTs that have either shown promising results in 
preclinical development, clinical trial stage, or that have been FDA approved.
4.1 Small molecule inhibitors of EZH2
As aforementioned, EZH2 is a lysine methyltransferase that is overexpressed and 
found to contribute to many cancer progressions including but not limited to breast, 
prostate, colon, ovarian, liver, bladder, lymphoma, skin, and lung cancer. The 
overabundance of EZH2 causes hypersilencing of genes that restrain proliferation 
and promotes differentiation [67]. As a result, several studies have been conducted 
to understand the mechanism of action and structure of the enzyme so that appro-
priate drugs can be developed to inhibit its aberrant activity. For example, FDA has 
approved the use of tazemetostat (EPZ6438) (Table 1), an EZH2 small molecule 
inhibitor, for the treatment of epithelioid sarcoma (not qualified for resection) in 16 
years and above patients. Tazemetostat has an inhibition constant (Ki) of 2.5nM and 
works by competitively inhibiting SAM binding site on EZH2 [32]. Another small 
molecule inhibitor, CPI-1205 (Table 1), completed phase 1 clinical trial for B-cell 
lymphoma and solid advanced tumor and is in phase 1b/2 clinical trial for metastatic 
castration-resistant prostate cancer (mCRPC) [130, 131]. Furthermore, another 
potent small molecule inhibitor, GSK2816126 (Table 1), which showed remarkable 
preclinical potential entered phase 1 clinical trial for the treatment of lymphoma 
and solid cancers but proved to be unsuitable target for inhibiting EZH2 due to its 
unfavorable pharmacokinetic profile [132]. More than 50 small molecule inhibitors 
for EZH2 are in preclinical development [133]. A few are highlighted in Table 1.
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Epigenetic 
enzyme
Small molecule 
inhibitors
Stage of 
development
Cancer treatment Reference
Lysine methyltransferases
EZH2 EPZ6438 
(Tazemostat)
FDA approved Epithelioid sarcoma [32]
Phase 1 clinical 
trial
Various lymphomas 
and
advanced solid 
tumors
[ClinicalTrials.
gov] Identifier: 
NCT03010982
GSK2816126 Phase 1 clinical 
trial
Lymphoma and 
advanced solid 
tumors
[132]
CP1-1205 Phase 1b/2 
clinical trial
B-cell lymphoma, 
advanced solid 
tumors metastatic 
castration-resistant 
prostate cancer 
(mCRPC)
[130, 131]
EI1 Preclinical 
stage
B-cell lymphoma 
with Y641 mutation
[141]
EPZ011989 Preclinical 
stage
Lymphoma [142]
UNC 1999 Preclinical 
stage
Diffused B-cell 
lymphoma with 
Y641N mutation 
and MLL rearranged 
leukemia
[143, 144]
hDOT1L EPZ5676 
(Pinometostat)
Phase 1 clinical 
trial
Acute myeloid 
leukemia (AML)/
acute lymphoblastic 
leukemia (ALL)
[137] 
[ClinicalTrials.
gov] Identifier: 
NCT03724084
EPZ 004777 Preclinical 
stage
MLL rearranged 
leukemia
[136]
SGC0946 Preclinical 
application
MLL rearranged 
leukemia
[145]
Protein Arginine Methyltransferases
PRMT5 GSK3326595(formerly 
EPZ015938)
Phase 1 clinical 
trial
Solid tumor and 
non-Hodgkin’s 
lymphoma
[ClinicalTrials.
gov] Identifier: 
NCT02783300
JNJ-64619178 Phase 1 clinical 
trial
[Clinical Trial 
identifier: 
NCT03573310]
EPZ015666 Preclinical 
stage
Mantle cell 
Lymphoma
[135]
PR5-LL-CM01 Preclinical 
stage
Colon and 
Pancreatic cancer
[114]
LLY-283 Preclinical Ovarian, lung, 
breast, gastric, skin, 
and hematological 
cancers
[140]
Table 1. 
List of representative small molecule inhibitors for EZH2, hDOT1L, and PRMT5.
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4.2 Small molecule inhibitors of hDOT1L
There are over 20 hDOT1L small molecule inhibitors and can be categorized into 
four groups based on their mode of action: (i) SAH(S-adenosyl-L-homocysteine)-
mimicking compounds; (ii) benzimidazole or (iii) urea group-containing com-
pounds; and (iv) carbamate-containing compounds [134]. The activity of human 
homolog of yeast DOT1L or hDOT1L is mostly dysregulated in a subset of acute 
myeloid leukemia that has MLL gene translocation. This results in an onco-MLL 
protein which aberrantly recruits hDOT1L to the promoter of MLL target genes. 
Together with other transcription factors, hDOT1L drives the overexpression of 
HoxA9 and HoxA7 which leads to leukemia [135]. Hence, the need for inhibitors 
of hDOT1L. The first potent inhibitor of this HMT was EPZ004777 (Table 1), but 
it failed to progress through clinical development due to poor pharmacokinetics 
[136]. Another small molecule inhibitor, EPZ5676 (pinometostat) (Table 1) with Ki 
of less than 0.08nM, was shown to have improved pharmacokinetics and has now 
completed phase 1 clinical trial [137].
4.3 Small molecule inhibitors of PRMT5
PRMT5 is overexpressed in a several types of cancers. There are currently over 50 
PRMT5 small molecule inhibitors, and PRMT5 is emerging as a hotspot for cancer 
targeted therapy [138]. Some small molecule inhibitors of PRMT5 are currently 
undergoing assessment in phase 1 clinical trial for non-Hodgkin lymphomas and 
solid cancers include GSK3326595 and JNJ-64619178 (Table 1). PRMT5 has also been 
implicated in the progression and metastasis of pancreatic and colon cancer. As a 
result, a lead compound, PR5-LL-CM01 (Table 1), has been discovered by our group 
to have more potent inhibitory properties compared to EPZ015666 in pancreatic and 
colon cancer cells [114]. However, EPZ015666 showed high potency in vitro and in 
mantle lymphoma cells with an IC50 of 22nM (Table 1) [139]. Another potent inhibi-
tor of PRMT5, LLY-283 (IC50 = 20 nM) (Table 1) showed an outstanding inhibition 
of breast, lung, skin, ovarian, and hematological cancer cells’ proliferation [140].
5. Conclusion, perspective, and future directions
Taken together, in this chapter, we discussed the important roles that epigenetic 
enzymes play in a variety of cancers. We also summarized several popular methods 
currently used for screening small molecule inhibitors of epigenetic enzymes. As 
shown in Table 1, we provided a list of representative small molecule inhibitors of 
HMT that are either FDA approved, or at preclinical or different stages of clinical 
trials. Notably, compared to the well-developed HDAC small molecule inhibitors, 
the development of small molecule inhibitors for HMTs is a rising and cutting-edge 
drug development area. We can envision that in the next 5~10 years, intense atten-
tion will continuously be drawn to the discovery of HMTs small molecule inhibitors. 
We have no doubt that many HMTs small molecule inhibitors will be shifted into 
clinical trials, more will be approved by FDA, and most likely, more members of 
HMTs will be targeted for cancer treatment. Additionally, it is very possible that 
novel HTS methods will emerge, which will further accelerate the discovery of 
anti-HMTs drugs. Moreover, it is viable that the clinical indications of HMTs small 
molecule inhibitors could be further expanded to other diseases beyond cancer. In 
summary, the development of new classes of anti-HMTs drugs will offer brand new 
and exciting opportunities for diseases treatment.
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